SANTA CLARA, Calif. & MARSHFIELD, Wis.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) and Marshfield Clinic today announced that researchers at Marshfield Clinic used the Affymetrix Drug Metabolizing Enzymes and Transporters (DMET) solution to discover a genetic variation associated with an individual’s response to the drug warfarin.
